Got a Question?
If you have a question for our guest, host or DRG please submit it here.
New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here
Physicians find new ways to share best practice
Guest: Mike Clayman, CEO and Co-Founder, Flexion Therapeutics
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Mike Clayman, CEO and co-founder of Flexion Therapeutics, about how the COVID-19 pandemic has affected their employees, distribution of their lead product Zilretta and their clinical trials. This discussion includes how Flexion Therapeutics has been able to return to some form of normality for both their employees, and their therapies, with the sales and distribution of Zilretta reaching pre-COVID-19 levels. Mike explores how they were able to raise over $100million dollars in May, despite the disruption, due to the belief in both Zilretta, and their exciting pipeline products that have been able to restart clinical trial research. They also discuss how the industry has embraced telemedicine during this time, and the belief that it’s here to stay. Watch the full episode to find out more.
About our Guest
Mike Clayman, CEO and Co-Founder, Flexion Therapeutics
Dr. Clayman is a co-founder of Flexion Therapeutics and has served as the President, Chief Executive Officer and as one of the directors since the inception in 2007. Dr. Clayman also serves as the Chairman of the board of directors of both Anokion SA and Ribometrix. Previously, Dr. Clayman had a lengthy career at Eli Lilly and Company, where he was most recently Vice President, Lilly Research Laboratories, and General Manager of Chorus, Lilly’s early-phase development accelerator. During his career at Lilly, Dr. Clayman also led its Global Regulatory Affairs division, the Cardiovascular Discovery Research and Clinical Investigation, Research and Development at Advanced Cardiovascular Systems, a medical device subsidiary of Lilly, the Internal Medicine Division, the Lilly Clinic, Lilly’s dedicated Phase 1 unit, and served as Chair of Lilly’s Bioethics Committee. Prior to his tenure at Lilly, Dr. Clayman was an Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the immunopathogenesis of renal disease.
About our Host
Mike Ward, Head of Thought Leadership, DRG
Mike Ward serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.
